The Los Angeles Post
U.S. World Business Lifestyle
Today: March 15, 2025
Today: March 15, 2025

Merck posts better-than-expected quarterly results on soaring Keytruda sales

The logo for Merck
April 26, 2024
Michael Erman - Reuters

By Michael Erman

(Reuters) - Merck & Co on Thursday reported better-than-expected fourth-quarter results on strong sales of its cancer immunotherapy Keytruda, now the world's biggest selling prescription medicine.

Merck reported adjusted earnings of 3 cents a share in the quarter, despite having to reduce its profit by $1.69 a share to account for a $5.5 billion payout to Japan's Daiichi Sankyo for the right to co-develop three cancer drugs. Analysts, on average, had expected the company to lose 11 cents a share, according to LSEG data.

Revenue for the quarter rose to $14.6 billion from $13.8 billion last year. Analysts, on average, had expected sales of $14.5 billion.

Sales of Keytruda rose 21% to $6.6 billion as the company was able to increase use of the drug in earlier stage cancers, topping analyst forecasts of $6.5 billion. For the full year, Keytruda racked up $25 billion in sales, surpassing sales of AbbVie's blockbuster arthritis drug Humira at its peak.

Merck forecast 2024 sales of between $62.7 and $64.2 billion, suggesting growth of as much as 6.8% year over year. Analysts, on average, are estimating 2024 sales of $63.5 billion.

The New Jersey-based drugmaker expects earnings of $8.44 to $8.59 per share, above analyst estimates of $8.42.

The company also said it is launching a restructuring program to optimize both its human health and animal health manufacturing operations.

It did not disclose any other details. Merck recorded a $190 million charge to its GAAP results in the quarter related to the restructuring.

Including costs from deals other than the Daiichi transaction and restructuring costs, the company reported a net loss of 48 cents per share for the quarter.

(Reporting by Michael Erman; Editing by Bill Berkrot)

Related Articles

Germany's Merck in advanced talks to acquire US biotech firm SpringWorks Novo Nordisk defends next-gen obesity drug CagriSema, details new trial US FDA approves Vertex's non-opioid painkiller Scientists say they are close to resurrecting a lost species. Is the age of de-extinction upon us?
Share This

Popular

Africa|Business|Economy|Environment

A river ‘died' overnight in Zambia after an acidic waste spill at a Chinese-owned mine

A river ‘died' overnight in Zambia after an acidic waste spill at a Chinese-owned mine
Business|Economy|Europe|Finance

Moody's upgrades Greece to investment grade on strong fiscal recovery and stability

Moody's upgrades Greece to investment grade on strong fiscal recovery and stability
Business|Political|Technology|US

Elon Musk's SpaceX asks US to address foreign trade barriers

Elon Musk's SpaceX asks US to address foreign trade barriers
Business|Finance|Stock Markets|US

Berkshire Hathaway director Olson to step down, Buffett opposes shareholder proposals

Berkshire Hathaway director Olson to step down, Buffett opposes shareholder proposals

Health

Americas|Health|US

Measles cases in Texas, New Mexico rise to 294 as outbreak spreads

Measles cases in Texas, New Mexico rise to 294 as outbreak spreads
Health|Science|US

FDA warns of misuse of laughing gas sold in colorful, flavored canisters

FDA warns of misuse of laughing gas sold in colorful, flavored canisters
Economy|Environment|Health|Political|US

Trump environmental rollbacks would boost pollution and endanger lives, former EPA heads say

Trump environmental rollbacks would boost pollution and endanger lives, former EPA heads say
Health|Science|US|World

US FDA warns against recreational use of 'laughing gas'

US FDA warns against recreational use of 'laughing gas'

Access this article for free.

Already have an account? Sign In